openPR Logo
Press release

Hemophilia Market Size to Grow Exponentially during the Assessment Period

12-06-2021 12:09 PM CET | Health & Medicine

Press release from: Transparancy Market Research

Hemophilia Market

Hemophilia Market

Hemophilia, a group of common hemorrhagic inherited disorders, that interferes with normal blood coagulation. The group of inherited ailments leads to excessive bleeding or prolonged bleeding, and may infest even after minor injuries. Its two most common types Hemophilia A and B fall into severe hereditary hemorrhagic disorders, where the former affects more than 4 lakhs males worldwide has a higher prevalence. The hemophilia market has made strides pivoting on the growing understanding of the etiology and pathophysiology. The condition affects all ethnic groups equally, and is usually diagnosed in the early months of the life. Especially in the developing world countries, the incidence has risen over the past few decades.

Rise in participation of interpersonal teams, notably incuding hematologists and immunologists, is a key trend expanding the avenue in the hemophilia market. The healthcare systems worldwide have increasingly adopted line of treatment that advance the long-term prognosis of patients. A key part of such initiatives is emphasizing on educating the patient population. Healthcare providers in the hemophilia market are promoting prophylactic treatment schedules. Subsequently, healthcare teams are stressing on improving adherence to such schedules, in order to improve the quality of life of patients. Further, a comprehensive care plans play critical role in reducing long-term complications.

Request Brochure for Report -

Hemophilia Market: Introduction

Genetic bleeding disorder is termed as hemophilia. It is a syndrome where patients lack necessary proteins required to clot the blood. This eventually leads to internal bleeding. The frequency and magnitude of bleeding depends upon the severity of hemophilia in a patient. The two major types of hemophilia are hemophilia A and hemophilia B. Hemophilia A is four times more prevalent than hemophilia B.
Hemophilia Market: Key Trends

Globally, one in every five patients suffers from hemophilia A. Hence, market players focus on R&D, which enables them to launch new drugs to provide necessary blood clotting proteins to patients. This has increased drug production in the global hemophilia market in the past few years. Rise in mergers and acquisitions among the key players fuels the growth of the global hemophilia market during the forecast period.
Surge in need of hemophilia medicines in order to limit blood loss is a major factor boosting the growth of the global hemophilia market. Moreover, unavailability of cure that can eliminate the disorder accelerates the growth of the global hemophilia market.
Growth of the global hemophilia market is attributed to focus on intense research & development in order to provide drugs that are more efficient for patients. Technological advancements in the health care sector also drive the global hemophilia market. Furthermore, the race to capture maximum opportunities by players contributes to the growth of the global hemophilia market.
Request for Analysis of COVID19 Impact on Hemophilia Market -

Presently, the world is struggling with the COVID-19 pandemic. COVID-19 leads to pneumonia, severe & acute respiratory disorders, multiple organ failure, and, in severe cases, death. The geriatric population is more prone to COVID-19. The global hemophilia market witnessed sluggish growth during the pandemic.
Governments of developing countries are making significant investments to modernize health care infrastructure in their respective countries, which is anticipated to increase access to health care. This is expected to drive the demand for hemophilia drugs, which in turn is likely to fuel the growth of the market from 2021 to 2031.
Pre Book Hemophilia Market Report -<ype=S

North America to Capture Major Share of Global Hemophilia Market

North America is projected to dominate the global hemophilia market from 2021 to 2031. This is attributed to favorable regulatory environment, rise in focus & interest in hemophilia research & diagnostics, and government funding for research on hemophilia drugs. Additionally, growth of the pharmaceutical & biotechnology industries and presence of well-established and high quality infrastructure for laboratory and clinical research propel the market in the region. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to rise in research & developmental activities, increase in government initiatives for improving health care, and surge in focus of key players in building or strengthening presence in the region
Read More Information:

Key Players Operating in Global Hemophilia Market

Several prominent players dominate the global hemophilia market. These players are adopting strategies such as mergers, collaborations, and partnerships in order to stay ahead of their rivals in the global hemophilia market. Some players are acquiring small and medium scale businesses in order to enhance their resource pool and customer base. These strategies offer a competitive edge to the players, which can be quite crucial in a highly competitive market. Key players hold a major share in their respective regions. Growth strategies adopted by leading players are likely to drive the global hemophilia market.

Major players operating in the global hemophilia market are:

Pfizer, Inc.
Bayer AG
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Other prominent players
Browse more Market Reports:

Insulin Pen Needles Market:

Artificial Intelligence in Diabetes Management Market:

Body Sensor Market:


Abbott is another key player operating in the global valvular heart disease market with vast product portfolio. Abbott has established its presence in the global market through acquisition of St. Jude Medical in 2017. In January 2019, Abbott acquired Cephea Valve Technologies, Inc. This acquisition enabled the company to strengthen its position in valvular heart disease market.


Medtronic offers its valvular heart disease products under its Cardiac & Vascular Group (CVG). In 2018, around 38% of the company’s revenue was contributed by its CVG business segment. Medtronic has one of the industry leading portfolio of Hemophilia products.

Browse more Market Reports:

Medical Foods Market:

Assistive Technologies Demand for Visually Impaired Market:

Veterinary Ventilators Market:


Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453


About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia Market Size to Grow Exponentially during the Assessment Period here

News-ID: 2486114 • Views: 172

More Releases from Transparancy Market Research

Nuclear Imaging Services Market Growth to Remain Stable during the Projection Pe …
Nuclear Imaging Services Market Nuclear medicine (NM) is a field of medical imaging that employs the usage of tiny quantities of radioactive chemicals for diagnosis as well as treatment of many illnesses. Nuclear imaging entails the application of methods that give quantitative as well as qualitative data on physiological processes inside the body of beings. Nuclear medicine procedures such as PET, scintiography, and single photon emission computed tomography (SPECT) make use
Near Infrared Imaging Market Estimated to Rise Profitably during the Foreseeable …
Global Near Infrared Imaging Market: Overview Near infrared imaging electromagnetic spectrum based imaging offers better clarity as compared to conventional imaging. It is The global near infrared imaging market is expected to witness an astounding growth during the forecast period 2018 to 2026. The rising trend of research activities to develop better and advanced diagnostics is projected to help the global near infrared market expand in the forthcoming years. An upcoming Transparency
Cough Suppressant Drugs Market Will Generate New Growth Opportunities in Upcomin …
Cough Suppressant Drugs Market - Snapshot Three types of medicines can ease a cough caused by a cold or bronchitis: cough suppressants, expectorants, and ointments you apply to your skin called topicals. Suppressants do their job by blocking your cough reflex. Dextromethorphan is the most common ingredient for this. You’ll see it listed as on the bottle or package. This type of medication isn’t used to treat a cough with mucus.
Sinusitis Treatment Market projected to expand at a CAGR of ~4% from 2021 to 203 …
Hip Replacement Implants Market: Introduction According to the report, the global hip replacement implants market was valued at US$ 5 Bn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031. The hip replacement implant is a device used in hip replacement surgery for damaged hip joint. The hip replacement surgery is widely performed and is known as total hip arthroscopy, wherein a surgeon replaces the

All 5 Releases

More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia Gene Therapy - A Pipeline Analysis Report
"The Report Hemophilia Gene Therapy - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" Hemophilia Gene Therapy: An insight Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing
Global Hemophilia Treatment Market to 2024
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Global hemophilia treatment market was valued at $10.2bn in 2015 and is forecast to grow at a modest 5.4% CAGR between 2015 and 2024, culminating
Hemophilia B Market Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include